Market Cap 103.47B
Revenue (ttm) 43.08B
Net Income (ttm) 7.54B
EPS (ttm) N/A
PE Ratio 10.99
Forward PE 10.42
Profit Margin 17.50%
Debt to Equity Ratio 1.09
Volume 3,914,934
Avg Vol 4,418,888
Day's Range N/A - N/A
Shares Out 2.03B
Stochastic %K 66%
Beta 0.38
Analysts Sell
Price Target $56.57

Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephr...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 8047 5000
Website: www.gsk.com
Address:
79 New Oxford Street, London, United Kingdom
ChipDistribution7
ChipDistribution7 May. 15 at 1:59 PM
Passing on $CBRS near ~$100B mcap. Bull case: real AI compute architecture shift, not just a cycle. Customer list is strong: OpenAI: $20B+ $AMZN AWS $META Llama Perplexity, $GSK, Mistral, Notion, AlphaSense Diversification away from G42 reduces single-driver risk. But timing risk remains: $NVDA Vera Rubin cycle (H2 2026) CUDA moat still dominant AI stack competition rising Feels like market already prices in near-perfect execution. Not rushing in, maybe $200 level. Follow me 👉@ChipDistribution7 for real-time updates and everything. Let’s make moves!
0 · Reply
BxxZ
BxxZ May. 15 at 11:25 AM
$SPRO $GSK So pathetic - ......
0 · Reply
BxxZ
BxxZ May. 15 at 10:24 AM
$SPRO $GSK Show some balls finally - it is time.... We can clearly see those Spro "snowballs" (Board&mgt) are just following Ur wishes!!!
0 · Reply
DDel
DDel May. 14 at 7:51 PM
0 · Reply
trenddetector
trenddetector May. 14 at 3:28 PM
$GSK is pushing harder into oncology after years of being known more for vaccines and respiratory drugs. They've got a growing cancer pipeline and their oncology sales posted solid growth in recent years. GSK's cancer treatments are featured on YourCancerPath.com — a free platform for patients navigating 22 cancer types, from diagnosis through treatment options. No fluff, no cost. 🔗 YourCancerPath.com #GSK #cancer #oncology
0 · Reply
ImadogImaMut
ImadogImaMut May. 14 at 12:31 PM
$SCYX Do we know the name of the new VP ? Why were earnings not used as a reminder about the vote ? Is it material that we made compliance ? But no mention as a milestone faking highlight where people like myself fought to support the company after the 770 pump and by purchasing more common shares I felt I supported the best interests of myself But also other shareholders who are long . We are aligned but this co is bei G manipulated by a foreign entity controlled and is none other than $GSK I would like to know if we officially made compliance ? Since we are in the US we are bound by the laws and rules but the co asks for a vote on ratios and mysterious new people that are offered inducements? These are material events and must be reported by the company to the shareholders that’s why it’s called “ material” 🍀☮️☕️
1 · Reply
zerodayrounder
zerodayrounder May. 14 at 1:44 AM
May 11: $GSK announces final £0.18 billion buyback tranche concluding June 26 May 12: Immunitas discloses €407.5 license deal for non-core inflammation drug with Boehringer-Ingelheim May 13: $SPRO releases Q1 report and earnings release clearly discussing coordination with GSK on the license and ALSO on "advancing corporate activities, including a clinical stage pipeline." Immunitas IMT-009 is ready for the clinic after good Phase 1/2a data but needs $$$. June 23 is a forcing function re the 120 million authorization imo. 30 day HSR review on tebi asset sale could start as soon as May 15, and conclude around June 15. Waiting til next week you are pushing up on June 18, then June 19 (a holiday) which would take out to June 22 (too close for comfort on shareholder vote) I would think SPRO/GSK/GSK want the tebi sale to be totally closed before the June 23 date as shareholders would understand they are funding a validated, growth biotech (Immunitas) w// great team vs some random drug pipeline.
1 · Reply
zerodayrounder
zerodayrounder May. 13 at 12:58 AM
File under: interesting $SPRO $GSK Immunitas platform validated? IMT-009 not a lead asset and not really related to GSK core areas of anti infectives and oncology Boehringer makes €407M bet on Immunitas’ inflammatory asset https://www.fiercebiotech.com/biotech/boehringer-furthers-inflammatory-expansion-eu407m-biobuck-bet-immunitas-asset
1 · Reply
DDel
DDel May. 12 at 6:28 PM
0 · Reply
JFais
JFais May. 12 at 1:30 PM
$XBI - $BMY following $GSK into massive collaboration with Hengrui Pharma... "Some analyses suggest China = a third of all pipeline projects worldwide!" Major changes needed at the FDA if US isn't going to fall completely behind 🚨
0 · Reply
Latest News on GSK
GSK price target lowered to 2,100 GBp from 2,250 GBp at Citi

2026-05-07T02:29:36.000Z - 8 days ago

GSK price target lowered to 2,100 GBp from 2,250 GBp at Citi


Big Pharma M&A set for mega year as patent expiries drive deal urgency

Fri, 01 May 2026 10:03:53 -0400 - 14 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency


Q1 2026 GSK plc Earnings Call Transcript

2026-04-30T05:06:05.000Z - 15 days ago

Q1 2026 GSK plc Earnings Call Transcript


GSK Reports Strong Q1 2026 Results with Revenue Growth

2026-04-29T12:03:12.000Z - 16 days ago

GSK Reports Strong Q1 2026 Results with Revenue Growth


GSK Raises 2031 Sales Forecast to Over GBP 40 Billion

2026-04-29T11:57:21.000Z - 16 days ago

GSK Raises 2031 Sales Forecast to Over GBP 40 Billion


GSK Expects Steady Growth Through 2026

2026-04-29T11:35:04.000Z - 16 days ago

GSK Expects Steady Growth Through 2026


GSK Reports Strong Q1 Sales Growth and Advancements in R&D

2026-04-29T11:33:47.000Z - 16 days ago

GSK Reports Strong Q1 Sales Growth and Advancements in R&D


GSK plc Earnings Call Transcript: Q1 2026

Apr 29, 2026, 7:00 AM EDT - 16 days ago

GSK plc Earnings Call Transcript: Q1 2026


GSK reaffirms 2031 sales outlook over GBP 40B

2026-04-29T10:25:36.000Z - 16 days ago

GSK reaffirms 2031 sales outlook over GBP 40B


GSK reports Q1 core EPS 46.5p, up 9% at CER

2026-04-29T10:13:35.000Z - 16 days ago

GSK reports Q1 core EPS 46.5p, up 9% at CER


GSK Earnings Boosted by Higher Specialty Medicine Sales

Wed, 29 Apr 2026 02:45:00 -0400 - 16 days ago

GSK Earnings Boosted by Higher Specialty Medicine Sales


GSK Q1 Core Profit Rises; Affirms 2026 Guidance

2026-04-29T06:35:46.000Z - 16 days ago

GSK Q1 Core Profit Rises; Affirms 2026 Guidance


GSK to Report Q1 Earnings with Strong Revenue Expectations

2026-04-28T18:04:30.000Z - 17 days ago

GSK to Report Q1 Earnings with Strong Revenue Expectations


GSK Receives Fast-Track Review for New Hepatitis B Treatment

2026-04-28T11:28:09.000Z - 17 days ago

GSK Receives Fast-Track Review for New Hepatitis B Treatment


GSK Secures Breakthrough Therapy Designation for Efimosfermin

2026-04-27T12:51:40.000Z - 18 days ago

GSK Secures Breakthrough Therapy Designation for Efimosfermin


GSK Faces Court Ruling Favoring TESARO in Dispute

2026-04-27T12:26:59.000Z - 18 days ago

GSK Faces Court Ruling Favoring TESARO in Dispute


GSK’s TESARO provides update on AnaptysBio litigation

2026-04-27T10:41:58.000Z - 18 days ago

GSK’s TESARO provides update on AnaptysBio litigation

ANAB


GSK Faces Legal Setback as AnaptysBio Wins Court Ruling

2026-04-24T21:27:17.000Z - 20 days ago

GSK Faces Legal Setback as AnaptysBio Wins Court Ruling


Top FTSE 100 shares to watch next week: Lloyds, Barclays, GSK, Natwest

Fri, 24 Apr 2026 03:28:20 -0400 - 21 days ago

Top FTSE 100 shares to watch next week: Lloyds, Barclays, GSK, Natwest


US FDA approves GSK's drug for liver disease related itching

Mar 19, 2026, 8:08 AM EDT - 2 months ago

US FDA approves GSK's drug for liver disease related itching


GSK gets US FDA approval for expanded use of RSV vaccine

Mar 13, 2026, 7:03 AM EDT - 2 months ago

GSK gets US FDA approval for expanded use of RSV vaccine


GSK licenses liver disease drug to Italy's Alfasigma

Mar 9, 2026, 3:16 AM EDT - 2 months ago

GSK licenses liver disease drug to Italy's Alfasigma


GSK to Buy 35Pharma for $950 Million

Feb 25, 2026, 5:05 AM EST - 2 months ago

GSK to Buy 35Pharma for $950 Million


GSK to buy 35Pharma for $950 million

Feb 25, 2026, 2:18 AM EST - 2 months ago

GSK to buy 35Pharma for $950 million


Frontier Biotechnologies strikes up to $1 billion deal with GSK

Feb 24, 2026, 6:21 AM EST - 2 months ago

Frontier Biotechnologies strikes up to $1 billion deal with GSK


3 International Stocks to Buy for 2026

Feb 5, 2026, 9:00 AM EST - 3 months ago

3 International Stocks to Buy for 2026

DEO SAP


GSK's Specialty Medicines Drive Solid Results

Feb 4, 2026, 2:45 AM EST - 3 months ago

GSK's Specialty Medicines Drive Solid Results


GSK forecasts slower sales growth in 2026

Feb 4, 2026, 2:03 AM EST - 3 months ago

GSK forecasts slower sales growth in 2026


GSK to buy food allergy drug maker RAPT in $2.2bn deal

Jan 20, 2026, 7:20 AM EST - 4 months ago

GSK to buy food allergy drug maker RAPT in $2.2bn deal

RAPT


GSK to buy RAPT Therapeutics for $2.2 billion

Jan 20, 2026, 2:11 AM EST - 4 months ago

GSK to buy RAPT Therapeutics for $2.2 billion

RAPT


ChipDistribution7
ChipDistribution7 May. 15 at 1:59 PM
Passing on $CBRS near ~$100B mcap. Bull case: real AI compute architecture shift, not just a cycle. Customer list is strong: OpenAI: $20B+ $AMZN AWS $META Llama Perplexity, $GSK, Mistral, Notion, AlphaSense Diversification away from G42 reduces single-driver risk. But timing risk remains: $NVDA Vera Rubin cycle (H2 2026) CUDA moat still dominant AI stack competition rising Feels like market already prices in near-perfect execution. Not rushing in, maybe $200 level. Follow me 👉@ChipDistribution7 for real-time updates and everything. Let’s make moves!
0 · Reply
BxxZ
BxxZ May. 15 at 11:25 AM
$SPRO $GSK So pathetic - ......
0 · Reply
BxxZ
BxxZ May. 15 at 10:24 AM
$SPRO $GSK Show some balls finally - it is time.... We can clearly see those Spro "snowballs" (Board&mgt) are just following Ur wishes!!!
0 · Reply
DDel
DDel May. 14 at 7:51 PM
0 · Reply
trenddetector
trenddetector May. 14 at 3:28 PM
$GSK is pushing harder into oncology after years of being known more for vaccines and respiratory drugs. They've got a growing cancer pipeline and their oncology sales posted solid growth in recent years. GSK's cancer treatments are featured on YourCancerPath.com — a free platform for patients navigating 22 cancer types, from diagnosis through treatment options. No fluff, no cost. 🔗 YourCancerPath.com #GSK #cancer #oncology
0 · Reply
ImadogImaMut
ImadogImaMut May. 14 at 12:31 PM
$SCYX Do we know the name of the new VP ? Why were earnings not used as a reminder about the vote ? Is it material that we made compliance ? But no mention as a milestone faking highlight where people like myself fought to support the company after the 770 pump and by purchasing more common shares I felt I supported the best interests of myself But also other shareholders who are long . We are aligned but this co is bei G manipulated by a foreign entity controlled and is none other than $GSK I would like to know if we officially made compliance ? Since we are in the US we are bound by the laws and rules but the co asks for a vote on ratios and mysterious new people that are offered inducements? These are material events and must be reported by the company to the shareholders that’s why it’s called “ material” 🍀☮️☕️
1 · Reply
zerodayrounder
zerodayrounder May. 14 at 1:44 AM
May 11: $GSK announces final £0.18 billion buyback tranche concluding June 26 May 12: Immunitas discloses €407.5 license deal for non-core inflammation drug with Boehringer-Ingelheim May 13: $SPRO releases Q1 report and earnings release clearly discussing coordination with GSK on the license and ALSO on "advancing corporate activities, including a clinical stage pipeline." Immunitas IMT-009 is ready for the clinic after good Phase 1/2a data but needs $$$. June 23 is a forcing function re the 120 million authorization imo. 30 day HSR review on tebi asset sale could start as soon as May 15, and conclude around June 15. Waiting til next week you are pushing up on June 18, then June 19 (a holiday) which would take out to June 22 (too close for comfort on shareholder vote) I would think SPRO/GSK/GSK want the tebi sale to be totally closed before the June 23 date as shareholders would understand they are funding a validated, growth biotech (Immunitas) w// great team vs some random drug pipeline.
1 · Reply
zerodayrounder
zerodayrounder May. 13 at 12:58 AM
File under: interesting $SPRO $GSK Immunitas platform validated? IMT-009 not a lead asset and not really related to GSK core areas of anti infectives and oncology Boehringer makes €407M bet on Immunitas’ inflammatory asset https://www.fiercebiotech.com/biotech/boehringer-furthers-inflammatory-expansion-eu407m-biobuck-bet-immunitas-asset
1 · Reply
DDel
DDel May. 12 at 6:28 PM
0 · Reply
JFais
JFais May. 12 at 1:30 PM
$XBI - $BMY following $GSK into massive collaboration with Hengrui Pharma... "Some analyses suggest China = a third of all pipeline projects worldwide!" Major changes needed at the FDA if US isn't going to fall completely behind 🚨
0 · Reply
Corvette22
Corvette22 May. 12 at 1:16 PM
$GSK this stock does nothing for five years, finally gets a bump and now its back down again
1 · Reply
zerodayrounder
zerodayrounder May. 12 at 12:18 AM
0 · Reply
zerodayrounder
zerodayrounder May. 11 at 7:44 PM
$SPRO following $GSK lower. Maybe similar to the GSK move that began on Jan 15 and was final flush before RAPT and a move higher into Q4 report.
0 · Reply
trenddetector
trenddetector May. 11 at 5:28 PM
$CYDY $GIL $JNJ $MRK $GSK Share www.YourCancerPath.com with your friends/family who are trying to navigate a cancer diagnosis. In addition to current treatments, you’ll find promising treatments and clinical trials that may be suited for you/them.
0 · Reply
zerodayrounder
zerodayrounder May. 11 at 3:14 AM
$SPRO $GSK one last thing, if GSK buys tebi it starts the 30 day HSR review this week and would conclude around June 15. The PDUFA is June 18. And the SPRO AGM is June 23. Also, if these hypothetical transactions (Tebi asset sale + reverse merger) were to be announced -- tomorrow -- they would be massively material subsequent events that would require significant footnotes in the 10Q that is due by May 15. I wonder if SPRO pushed back the Q1 report til Wednesday to give the accounting team and PwC auditors a little extra time to sign off on subsequent event disclosures. Waiting til May 18 is pushing the timelines super duper close IF these ideas are anywhere near reality. You also risk leaks if lots of parties are in the know on these transactions including auditors, lawyers, advisors, insiders etc etc
0 · Reply
zerodayrounder
zerodayrounder May. 10 at 2:29 PM
1 · Reply
zerodayrounder
zerodayrounder May. 9 at 6:42 PM
$SPRO $GSK hopefully the Barney's and the Limey's are working this weekend https://www.youtube.com/watch?v=gArnm_Uicsw
0 · Reply
zerodayrounder
zerodayrounder May. 9 at 12:26 AM
$GSK frenemy Shionogi (ViiV Healthcare JV partner; AMR challenger) reports on Tuesday in Japan. Shionogi rumored to be the buyer of $ITRM Orlynvah out of the liquidation proceedings (according to that group of internet sleuths). Perhaps GSK wants to front-run Shionogi by announcing acquisition of tebipenem rights and the reverse merger Tx's considered ad nauseum on my stream to set the narrative for oral carbapenems for cUTI as #1 player in AMR (as the GSK Chairman discussed at the AGM) while funding another shot on goal in oncology space. $SPRO Q1 earnings just becoms a date to report Q1 numbers and file 10-Q with the fireworks happening on Monday?
2 · Reply
zerodayrounder
zerodayrounder May. 8 at 2:37 PM
$SPRO $GSK "let me tell you somethin', ya suspect, yeah you." 🫵 https://www.youtube.com/watch?v=OHSYWIAAY2o
0 · Reply
Fingerlickengood
Fingerlickengood May. 7 at 5:58 PM
$CDXS $GSK Guaranteed Codexis‘ Code Evolver and possibly Eco Synthesis platform as well will be involved to assist with enzyme technology to mass produce! https://www.pharmaceutical-technology.com/news/gsk-siranbio-1bn-licensing-deal-sa030-metabolic-disease/
0 · Reply
Fingerlickengood
Fingerlickengood May. 7 at 5:53 PM
$CDXS $GSK https://www.thepharmaletter.com/biotech-news/gsk-bets-on-visceral-fat-science-with-1-billion-siranbio-deal
0 · Reply
Fingerlickengood
Fingerlickengood May. 7 at 5:48 PM
$CDXS $GSK https://www.sec.gov/Archives/edgar/data/1200375/000120037524000009/cdxs-20231231.htm
0 · Reply